Jefferies lowered GSK (NYSE:GSK) to hold, citing a valuation disconnect between fundamentals and price. Jefferies said it ...
Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...
Q3 2024 Earnings Call Transcript November 7, 2024Dynavax Technologies Corporation beats earnings expectations.
Detailed price information for Dynavax Technologies (DVAX-Q) from The Globe and Mail including charting and trades.